Department of Surgery, Hoag Memorial Hospital Presbyterian, Newport Beach, CA, USA.
Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Ann Surg Oncol. 2017 Oct;24(10):3082-3087. doi: 10.1245/s10434-017-5934-z. Epub 2017 Aug 1.
Two prospective, randomized trials, TARGIT-A and ELIOT, have shown intraoperative radiation therapy (IORT) to be a safe alternative to whole breast radiation therapy following breast-conserving surgery for selected low-risk patients. However, minimal data are available about the clinical effectiveness of this modality of treatment using the Xoft Axxent Electronic Brachytherapy (eBx) System.
A total of 201 patients with 204 early-stage breast cancers were enrolled in a prospective X-ray IORT trial from June 2010 to September 2013. All tumors were treated with breast-conserving surgery and IORT. Data were collected at 1 week, 1 month, 6 months, 1 year, and yearly thereafter.
With a median follow-up of 50 months, there have been seven ipsilateral breast tumor events (IBTE), no regional or distant recurrences, and no breast cancer-related deaths. One IBTE was within the IORT field, four outside of the IORT field but within the same quadrant as the index cancer, and two were new biologically different cancers in different quadrants. Three events were in patients who deviated from the protocol criteria. Kaplan-Meier analysis projects that 2.9% of patients will recur locally at 4 years.
Recurrence rates observed in this trial were comparable to those of the TARGIT-A and ELIOT trials as well as the retrospective TARGIT-R trial. The low complication rates previously reported by our group as well as the low recurrence rates reported in this study support the cautious use and continued study of IORT in selected women with low-risk breast cancer.
两项前瞻性、随机试验(TARGIT-A 和 ELIOT)表明,对于选择的低危患者,在保乳手术后,术中放疗(IORT)是全乳放疗的一种安全替代方法。然而,使用 Xoft Axxent 电子近距离放射治疗(eBx)系统,关于这种治疗方式的临床疗效的数据很少。
2010 年 6 月至 2013 年 9 月,我们共纳入了 201 例 204 例早期乳腺癌患者,参加了一项前瞻性 X 射线 IORT 试验。所有肿瘤均采用保乳手术和 IORT 治疗。数据在术后 1 周、1 个月、6 个月、1 年和之后每年收集。
中位随访 50 个月,有 7 例同侧乳房肿瘤事件(IBTE),无区域或远处复发,无乳腺癌相关死亡。1 例 IBTE 位于 IORT 野内,4 例位于 IORT 野外但与索引癌相同象限内,2 例为不同象限内新的生物学不同的癌症。3 例事件发生在偏离方案标准的患者中。Kaplan-Meier 分析预测 4 年内 2.9%的患者会局部复发。
该试验观察到的复发率与 TARGIT-A、ELIOT 试验以及回顾性 TARGIT-R 试验相当。我们小组先前报道的低并发症率以及本研究报道的低复发率支持在选择的低危乳腺癌女性中谨慎使用和继续研究 IORT。